SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ — Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June … Read more
– Nuvaxovid™ de Novavax recibe la opinión positiva del CHMP para la autorización de comercialización completa para la prevención de la COVID en la UE GAITHERSBURG, Md., 29 de mayo de 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), una compañía global que promueve vacunas basadas en proteínas con su novedoso adyuvante Matrix-M™, anunció hoy que … Read more
GAITHERSBURG, Maryland, 29 mai 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), une entreprise mondiale qui fait progresser les vaccins à base de protéines avec son nouvel adjuvant Matrix-M™, a annoncé aujourd’hui que Nuvaxovid™ (NVX-CoV2373) a été recommandé pour une autorisation de mise sur le marché (AMM) complète pour une utilisation en tant que série primaire … Read more
SHANGHAI, 29 mai 2023 /PRNewswire/ — Le système μFR® de 4e génération de Pulse Medical Technology, Inc. (Pulse Medical) a reçu la désignation de dispositif révolutionnaire (Breakthrough Device) de la FDA. Pulse Medical, fondée en 2015 et située à Shanghai, en Chine, se consacre au développement d’une technologie innovante pour un diagnostic précis et un traitement optimal des patients atteints … Read more
SHANGHAI, 29 de mayo de 2023 /PRNewswire/ — El sistema μFR® de cuarta generación de Pulse Medical Technology, Inc. (Pulse Medical) ha recibido la designación de dispositivo innovador de la FDA. Pulse Medical, fundada en 2015, ubicada en Shanghái, China, se dedica a desarrollar tecnología innovadora para el diagnóstico preciso y el tratamiento óptimo de pacientes … Read more
GAITHERSBURG, Maryland, 27. Mai 2023 /PRNewswire/ — Novavax, Inc. Nasdaq: NVAX), ein globales Unternehmen, das Impfstoffe auf Proteinbasis mit seinem neuartigen Matrix-M™-Adjuvans entwickelt, gab heute bekannt, dass Nuvaxovid™ (NVX-CoV2373) in der Europäischen Union (EU) nach einer positiven Stellungnahme der European Medicines Agency für Medicinal Products for Human Use (CHMP) zur vollständigen Zulassung als Erstimpfung bei Personen … Read more
SHANGHAI, 26. Mai 2023 /PRNewswire/ — Das μFR®-System der vierten Generation von Pulse Medical Technology, Inc. (Pulse Medical) hat von der FDA den Status eines bahnbrechenden Geräts erhalten. Pulse Medical wurde in 2015 gegründet und hat seinen Sitz in Shanghai, China, und widmet sich der Entwicklung innovativer Technologie für eine präzise Diagnose und optimale Behandlung … Read more
LAKE FOREST, Calif., May 26, 2023 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 175,000 units (the “Units”), with each Unit consisting of one share of BIOLASE’s Series H Convertible Redeemable Preferred Stock, par value $0.001 per … Read more
SHANGHAI, May 26, 2023 /PRNewswire/ — Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation. Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosis and optimal treatment of patients with pan-vascular disease. Pulse Medical has been pioneering and … Read more
GAITHERSBURG, Md., May 26, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 … Read more